Oruka Therapeutics, Inc. (ORKA) shares jumped 21.79 percent to $84.14, gaining $15.11 on Monday, after reporting strong interim Phase 2a clinical data for its lead drug candidate in psoriasis.
The stock is currently trading at $84.14, compared to a previous close of $69.03 on the Nasdaq. It reached an intraday high of $91.00 and a low of $82.18, with trading volume of 3.72 million shares.
The company announced positive results from its EVERLAST-A trial evaluating ORKA-001, a next-generation IL-23p19 monoclonal antibody for moderate-to-severe plaque psoriasis. The data showed that 63.5 percent of treated patients achieved complete skin clearance at Week 16, with 83 percent reaching PASI 90, highlighting robust efficacy.
The stock's 52-week range is $8.91 to $91.00.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.